Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | GRPR | P30550 | 4/20 | 0.37 |
| ▸ | CALCR | P30988 | 4/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | NMBR | P28336 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15744682 | 0.95 | MMP3 (0.40) | CRHR1CRHR2GRPRCALCRAPLNR | |
| SCHEMBL26403817 | 0.83 | MMP3 (0.42) | GRPRAPLNRMMP3 | |
| SCHEMBL15745525 | 0.82 | APLNR (0.36) | CRHR1CRHR2GRPRCALCRAPLNR | |
| SCHEMBL2623712 | 0.82 | APLNR (0.40) | CRHR1CRHR2APLNRF2 | |
| SCHEMBL26019657 | 0.80 | CTSS (0.40) | APLNR | |
| SCHEMBL22387819 | 0.78 | CTSS (0.40) | — | |
| SCHEMBL15744687 | 0.77 | APLNR (0.40) | CRHR1CRHR2APLNRF2GHSR | |
| SCHEMBL19084167 | 0.77 | APLNR (0.34) | CRHR1CRHR2GRPRCALCRAPLNR | |
| SCHEMBL19084162 | 0.77 | APLNR (0.36) | CRHR1CRHR2APLNRF2GHSR | |
| SCHEMBL15745484 | 0.77 | CRHR1 (0.35) | CRHR1CRHR2GRPRCALCRAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190700-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | BAKARE OLADAPO (US) | 2017-07-06 | — | — | US | disclosed |
| US-9492560-B2 | Emetine derivatives, prodrugs containing same, and methods of treating conditions using same | HOWARD UNIVERSITY | 2016-11-15 | — | — | US | disclosed |
| US-20140148377-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | HOWARD UNIVERSITY | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190700-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | EML4, MCL1, ERAP2 | CRHR1 3307/4885CRHR2 2610/4885GRPR 2713/4885 |
| US-20140148377-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | EML4, MCL1, ERAP2 | CRHR1 3307/4885CRHR2 2610/4885GRPR 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.